Platelet-derived growth factor (PDGF)-B is a proto-oncogene capable of transforming fibroblasts. Using adenoviral vectors, we tested whether endogenous PDGF-B expression in human skin xenotransplants leads to changes in the expression of ␣5 and ␣2 integrin subunits and whether integrin overexpression leads to PDGF-related changes in the skin. In vitro, transduction of fibroblasts with PDGF-B or the integrin ␣5 subunit stimulated multilayered growth and spindle-type morphology, both markers of mesenchymal cell transformation. In vivo, PDGF-B transduction of the human dermis was associated with up-regulation of collagen and fibronectin synthesis, increases in ␣5 and ␣2 integrin subunit expression, vessel formation, and proliferation of fibroblasts, keratinocytes, and pericytes. A similar stromal response was induced when ␣5 and ␣2 integrin subunits were overexpressed in the human dermis, suggesting that integrins play a major role in the induction of a transformed phenotype of fibroblasts by PDGF-B. (Lab Invest 2001, 81:1263-1274. P latelet-derived growth factor (PDGF) is a normal constituent of platelets from which it is released by degranulation of ␣ granules at sites of injury (Ross et al, 1986) . PDGF-A and PDGF-B can function as homo-or heterodimers of 28 to 35 kDa (Kohler and Lipton, 1974; Ross et al, 1974; Westermark and Wasteson, 1976) . PDGF-BB and PDGF-AB bind to the PDGF␤ receptor and, to a lesser extent, the PDGF␣ receptor, both present predominantly on mesenchymal cells. However, PDGF-AA homodimers bind only to the PDGF␣ receptor (Hart et al, 1988; Heldin et al, 1988) . PDGF-B exerts a mitogenic effect on fibroblasts (Kohler and Lipton, 1974) and smooth muscle cells (Ross et al, 1974) , which express the PDGF␤ receptor and normally do not secrete PDGF-B. Secretion of PDGF-B can be induced with peptide regulatory factors, such as transforming growth factor-␤ (Soma and Grotendorst, 1989) . Binding of PDGF-B to PDGF␤ induces receptor dimerization and is associated with autophosphorylation and binding of downstream modulators to the cytoplasmic domain of the receptor (Benito and Lorenzo, 1993; Bornfeldt et al, 1995) . Malignant cells often express PDGF-B constitutively (Fahrer et al, 1989; Ito et al, 1990; Leveen et al, 1990; Mauro and Bulfone, 1990) , and in glioma, PDGF-B is an autocrine growth factor (Mauro and Bulfone, 1990) . Other tumors, such as melanomas, lack the receptor and produce the factor for stimulating normal cells in the tumor stroma (Forsberg et al, 1993) .
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latelet-derived growth factor (PDGF) is a normal constituent of platelets from which it is released by degranulation of ␣ granules at sites of injury (Ross et al, 1986) . PDGF-A and PDGF-B can function as homo-or heterodimers of 28 to 35 kDa (Kohler and Lipton, 1974; Ross et al, 1974; Westermark and Wasteson, 1976) . PDGF-BB and PDGF-AB bind to the PDGF␤ receptor and, to a lesser extent, the PDGF␣ receptor, both present predominantly on mesenchymal cells. However, PDGF-AA homodimers bind only to the PDGF␣ receptor (Hart et al, 1988; Heldin et al, 1988) . PDGF-B exerts a mitogenic effect on fibroblasts (Kohler and Lipton, 1974) and smooth muscle cells (Ross et al, 1974) , which express the PDGF␤ receptor and normally do not secrete PDGF-B. Secretion of PDGF-B can be induced with peptide regulatory factors, such as transforming growth factor-␤ (Soma and Grotendorst, 1989) . Binding of PDGF-B to PDGF␤ induces receptor dimerization and is associated with autophosphorylation and binding of downstream modulators to the cytoplasmic domain of the receptor (Benito and Lorenzo, 1993; Bornfeldt et al, 1995) . Malignant cells often express PDGF-B constitutively (Fahrer et al, 1989; Ito et al, 1990; Leveen et al, 1990; Mauro and Bulfone, 1990) , and in glioma, PDGF-B is an autocrine growth factor (Mauro and Bulfone, 1990) . Other tumors, such as melanomas, lack the receptor and produce the factor for stimulating normal cells in the tumor stroma (Forsberg et al, 1993) .
In fibroblasts, activation of the PDGF␤ receptor leads to transformation (Gazit et al, 1984; Fleming et al, 1992) , defined as loss of contact inhibition in monolayer cultures and anchorage-independent growth in soft agar (Fry et al, 1990) . Immortalized, but nontumorigenic murine fibroblasts can form tumors in mice when transduced with the proto-oncogene c-sis (Kim et al, 1994) ; the PDGF-B gene shares 94% sequence homology with the avian viral oncogene, v-sis (Waterfield et al, 1983) , further underscoring the potential for fibroblast transformation by PDGF-B (Benito and Lorenzo, 1993; Huang et al, 1984; Leal et al, 1985; Valgeirsdottir et al, 1995) .
Besides its growth-stimulating activity, PDGF-B upregulates expression of ␣5 and ␣2 integrin subunits, which heterodimerize with the ␤1 integrin subunit (Ahlen and Rubin, 1994; Gailit et al, 1996) . The ␣5␤1 integrin is the major fibronectin receptor present on most cells; it mediates adhesion, migration, assembly of extracellular matrix, and signal transduction (Greiling and Clark, 1997; Wu et al, 1993) , which can induce gene expression and affect transit through the cell cycle (Juliano and Varner, 1993) . The induction of ␣5 integrin monomer expression may be involved in the regulation of tumor cell growth and differentiation, provided that ␤1 integrin subunit is available. In colon carcinomas, overexpression of ␣5 integrin subunit leads to increased tumorigenicity (Gong et al, 1997) when fibronectin is present. In the absence of fibronectin, ␣5␤1 integrin expression induces a negative growth signal that can only be overcome when cells are provided with fibronectin (Allen-Hoffmann et al, 1990; Juliano and Varner, 1993; Varner et al, 1995) .
PDGF-B increases production of fibronectin in cells (Allen-Hoffmann et al, 1990 ) and enhances collagen synthesis as part of the wound-healing response (Pierce et al, 1995) . We hypothesized that the phenotype induced in vivo by PDGF-B in fibroblasts is due to the up-regulation of integrin ␣5 and ␣2 subunits, which, in turn, increase fibronectin and collagen production. We further questioned whether the induced changes by PDGF-B in human skin can be partially mimicked by infection with integrin ␣5 or ␣2 subunits. To study the effects of locally overproduced human PDGF-B and integrins ␣5 and ␣2, we transfected human fibroblasts with adenoviral vectors carrying the PDGF-B, ␣5, or ␣2 genes (PDGF-B/Ad5, ␣5/Ad5, and ␣2/Ad5, respectively). Replication-defective adenoviruses infect proliferating and nonproliferating cells and induce gene expression with high efficiency (Kozarsky and Wilson, 1993) . The biological effects of PDGF-B, ␣5, and ␣2 integrin subunit overexpression were analyzed in human skin grafted to immunodeficient mice. The grafted skin maintains its human-specific architecture throughout the lifetime of the animals and is well-suited for studies of human skin cell transformation (Juhasz et al, 1993a; Soballe et al, 1996) . Our results demonstrate that PDGF-B transduction of fibroblasts induces an increase in fibronectin and collagen, leads to up-regulation of ␣5 and ␣2 integrin subunits, increases vessel formation and the numbers of undifferentiated keratinocytes in the epidermis as well as pericytes. A transformed phenotype, ie, loss of contact inhibited growth, was also observed in fibroblasts overexpressing ␣5 in culture. Those cells showed up-regulated production of fibronectin, which was mostly pronounced in human skin grafts compared to cultured cells. Infection of fibroblasts in human skin xenotransplants with either integrin ␣5 or ␣2 subunits also enhanced fibronectin and collagen production. These changes resembled the transformed phenotype after PDGF-B infection, except that there was less growth stimulation. Our in vitro experiments with transduced fibroblasts demonstrate that both PDGF-B and ␣5 integrin enhance survival of fibroblasts.
Results

In Vitro and In Vivo Expression of PDGF after Transduction with PDGF-B/Ad5
Western blot analysis of lysates from primary human fibroblasts transduced with a replication-deficient adenoviral vector carrying the PDGF-B gene (PDGF-B/ Ad5) revealed a 36 kDa band representing the PDGF-BB homodimer and several bands of precursor proteins, whereas LacZ transduced or nontransduced fibroblasts showed neither the mature nor precursor bands (Fig. 1A) . Western analysis of lysates of fibroblasts transduced with PDGF, ␣5, or LacZ revealed high levels of ␣5 integrin in ␣5-transduced cells, lower levels in PDGF-B-transduced cells, and very little ␣5 in LacZ-or nontransduced cells (data not shown). Beta1 integrin was present at high levels independent of adenoviral transduction. Mitogenic activity in the culture supernatant of mouse fibroblasts was abrogated by addition of anti-PDGF-BB antibodies, suggesting that most of the activity in the supernatant was due to PDGF-BB. Overexpression of PDGF-B in human fibroblasts was mitogenic and stimulated [
3 H]-thymidine incorporation significantly, demonstrating the biological activity of adenovirus-induced PDGF-BB secretion (data not shown). Extractions of human skin injected 3 days earlier with PDGF-B/Ad5 revealed that two isoforms of PDGF, PDGF-AA and PDGF-AB/BB, were more highly expressed compared with skin injected with PBS or LacZ/Ad5 (Fig. 1B) . Series of bands of precursor proteins, down to 30 kDa, were detected for both PDGF-AA and PDGF-AB/BB in the lysates. The lowest bands for both isoforms are shown in Figure  1B , accounting for about 32 kDa for PDGF-AA and 34 kDa for PDGF-AB/BB. Seven days after injection there was still a higher production of PDGF-AA and PDGF-AB/BB after PDGF-B/Ad5 injection compared with LacZ/Ad5. The increase in expression of PDGF-BB was confirmed by ELISA, in which a significant increase after 3 and 7 days was observed (p Ͻ 0.05; Fig.  1C ).
Human Skin Remodeling by Intradermal PDGF-B Transduction
Human skin xenografts injected once with PDGF-B/Ad5 became raised, with increased soft tissue growth after 3 days ( Fig. 2A, top) , compared with their appearance after injection with LacZ/Ad5 ( Fig. 2A, bottom) or before injection (Fig. 2B ). Histological analysis of hematoxylin and eosin (H&E)-stained sections revealed dermal hypercellularity and irregular epidermal hyperplasia 3 days after PDGF-B/Ad5 injection (Fig. 2C) , which was minimal in sections from the LacZ/Ad5 control group (Fig. 2D) . After 3 days, PDGF-B/Ad5-injected grafts showed intense expression of PDGF-B in the dermis, with no expression in the epidermis (Fig. 2E) . In contrast, PDGF-B could not be detected in LacZ/Ad5 (Fig. 2F ) or in ␣5/Ad5-injected skin (data not shown). Injection with ␣5/Ad5 integrin led to phenotypically similar changes as PDGF-B/Ad5. Alpha 5 integrin was found to be expressed in the dermis (Fig. 3F ).
Comparison of Changes in Human Skin after Transduction with Adenoviral Vectors for ␣5 and ␣2
Integrin Subunits and Those Resulting from PDGF-B Overexpression
Seven days after transduction, immunostaining of human skin grafts confirmed the morphological reNesbit et al modeling induced by PDGF-B, ␣5, or ␣2 integrin subunits, compared with LacZ injected skin (Fig. 3) . The dermis showed strong and diffuse expression of fibronectin after PDGF-B and ␣5 integrin injection (Fig. 3, A and B) . A slight increase in fibronectin was also found in skin after ␣2 integrin injection (Fig. 3C ), which was in contrast to sections of skin injected with LacZ/Ad5 (Fig. 3D) . Expression of the ␣5 integrin subunit was up-regulated by PDGF-B (Fig. 3E) , and a strong, but more focal expression of ␣5 integrin was found after injection with ␣5 (Fig. 3F) . Injection with either ␣2 integrin or LacZ did not show a substantial expression of ␣5 (Fig. 3 , G and H).
Three days after intradermal injection with either PDGF-B or ␣2 integrin adenoviral vectors, massive collagen deposition was visualized by Masson's trichrome (Fig. 4 , A and C, respectively), but only a slight increase in production of collagen was detected after injection with ␣5 ( Fig. 4B ) compared with LacZ ( Fig. 4D ). Strong positive, focal staining for ␣2 integrin subunit was observed in the dermis after injection of PDGF-B and ␣2 integrin adenoviral vectors (Fig. 4 , E
Figure 1.
Production of platelet-derived growth factor (PDGF) isoforms in vitro and in vivo after transduction with PDGF-B using an adenoviral vector. A, Western blot analysis of PDGF-BB protein in lysates of fibroblasts (FF2030) transduced with either PDGF-B, LacZ, or nontransduced PBS. Equal quantities of lysate (100 g) were electrophoresed in 15% polyacrylamide gels under nonreducing conditions and incubated with polyclonal goat anti-human PDGF-BB antibody. B, Western blot analysis of extracts of human skin injected 3 or 7 days earlier with PDGF-B/Ad5, LacZ/Ad5 at 5 ϫ 10 8 plaque-forming units (pfu)/cell, or PBS. Equal quantities of protein (50 g) were loaded onto 15% gels under nonreducing conditions and incubated with a monoclonal mouse anti-human PDGF-BB or polyclonal goat anti-human PDGF-AA antibody at 2 g/ml. Blots were reprobed with anti-␤-actin antibody. Lane 1, Lysates of fibroblasts (FF2030) transduced with PDGF-B at Day 2; Lane 2, human skin injected with PBS at Day 3; Lane 3, human skin injected with LacZ at Day 3; Lane 4, human skin injected with PDGF-B at Day 3; Lane 5, human skin injected with LacZ at Day 7; Lane 6, human skin injected with PDGF-B at Day 7. C, PDGF-B levels in human skin extracts after injection with PDGF-B/Ad5, LacZ/Ad5 at 5 ϫ 10 and G, respectively), compared with LacZ (Fig. 4H) . No increase in positive staining for ␣2 integrin was found after ␣5 integrin injection (Fig. 4F) .
Further changes in skin morphology after PDGF-B, ␣5, and ␣2 integrin subunit transduction are shown in Figure 5 . Staining for chondroitin sulfate proteoglycan, a marker of vascular smooth muscle cells and pericytes, showed perivascular positivity and dermal focal positive staining. Compared with LacZ (Fig. 5D ), an increase in positive staining was observed after injection with PDGF-B (Fig. 5A) , ␣5 (Fig. 5B) , and ␣2 (Fig.  5C ) integrin subunits (ϫ80). Staining for CD31 (PECAM-1), an endothelial cell marker, demonstrated the strong angiogenic effect of PDGF-B-injected (Fig.  5E ) compared with LacZ-injected skin (Fig. 5F ). PDGF-B transduction also led to an increase in undifferentiated keratinocytes (Fig. 4, G and H) . Staining for cytokeratins 5 and 8 showed multiple layers of undifferentiated keratinocytes in the basal layer in PDGF-B-injected skin (Fig. 5G ) compared with LacZ/Ad5-transduced human skin, which had a single layer of undifferentiated keratinocytes in the basal layer (Fig.  4H) . Staining for Mac-1 (mouse CD11b), a marker for mouse macrophages, did not show any differences in infiltration between LacZ/Ad5-and PDGF-B/Ad5-, ␣5/ Ad5-, or ␣2/Ad5-injected skin. There was no overall significant increase in inflammatory cells compared with PBS-injected human skin.
Changes in Morphology In Vitro after Transduction with PDGF-B/Ad5 or ␣5/Ad5 and Enhanced Survival of Human Fibroblasts In Vivo
Normal human fibroblasts transduced with PDGF-B had spindle morphology and lost contact inhibition by growing in multiple layers (Fig. 6A) , whereas control cultures transduced with LacZ (Fig. 6B ) or nontransduced (Fig. 6D) showed a flat morphology and remained contact-inhibited. Like PDGF-B-transduced cultures, fibroblasts transduced with ␣5 integrin subunit grew in multiple layers (Fig. 6C) . Fibroblasts overexpressing PDGF-B grew anchorage independently in soft agar at up to 10% colony-forming efficiency (p Ͻ 0.05); colonies contained 20 or more cells (not shown). In contrast nontransduced or ␣5-transduced fibroblasts showed no significant colony formation. Small colonies of four cells at 1% to 2% efficiency were seen in cells transduced with LacZ. PDGF-B-induced proliferation of transduced fibroblasts was significantly inhibited by using a monoclonal antibody (MAb) against ␣5 (10 g/ml) (not shown), as measured by [
3 H]-thymidine incorporation. Marginal inhibition was achieved in fibroblasts transduced with LacZ or nontransduced. No inhibition of proliferation was observed in PDGF-B-transduced fibroblasts when incubated with control IgG (100 g/ml) (not shown). Human dermal fibroblasts, overexpressing PDGF-B and injected into severe combined immunodeficiency (SCID) mice, remained viable for at least 21 days, and lesions developed their own vasculature (Fig. 6E) . After 35 days, subcutaneous lesions were no longer palpable, and after 60 days, all human cells were gone at the injection site. In contrast, fibroblasts that were transduced with LacZ 24 hours earlier or nontransduced underwent massive necrosis within 3 days (Fig.  6F) , and by Day 5, only cell debris was detected. A similar prolonged survival as for PDGF-B was observed for fibroblasts transduced before injection with ␣5/Ad5 (shown in Fig. 6G after 10 days) . The lesions were surrounded by stroma and started to disappear after 2 to 3 weeks. In both types of lesions, nuclear staining with Hoechst dye showed that the center of the lesion contained human cells mixed with a few murine cells, as indicated by a uniform staining pattern of human rather than mouse cells.
Discussion
Endogenous overexpression of PDGF-B by adenoviral vectors induces multiple biological responses, both in vitro in human fibroblasts and in vivo in human skin. These effects include stimulation of fibroblast growth in vitro and in vivo, induction of matrix protein production, paracrine stimulation of epidermal keratinocytes, and prolonged survival of fibroblasts after in vivo injection.
PDGF-B/Ad5 transduction of human fibroblasts stimulated anchorage-independent growth in soft agar, loss of contact inhibition, and a spindle-type morphology, which are all known markers of mesen- Injection of PDGF-B, ␣5, and ␣2 integrin subunits with adenoviral vectors induces similar changes in expression of collagen and its receptor. Human skin grafts were injected with either PDGF-B (A and E), ␣5 integrin (B and F), ␣2 integrin (C and G), or LacZ (D and H). The skin grafts were stained 3 days later for collagen visualized with Masson's trichrome (A to D) or ␣2 integrin (E to H). Magnification, ϫ80.
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chymal cell transformation. Loss of contact inhibition in vitro and spindle-type morphology was also achieved by overexpression of ␣5 integrin, whereas in soft agar no anchorage-independent growth was observed. The loss of ␣1 integrin and the increase in ␣5 integrin expression have been demonstrated in vitro in response to exogenous PDGF-B (Gailit et al, 1996) .
Mitogenic stimulation of smooth muscle cells by PDGF-B further suggests that ␣5␤1 integrins regulate growth through a pathway that is distinct from the growth factor-activated MAP kinase pathway (Hedin et al, 1997) .
The remodeling of human dermis after PDGF-B transduction was similar to changes seen in the early stages of wound healing, which are also associated with ␣5 integrin and fibronectin up-regulation (Juhasz et al, 1993b) . The increased production of matrix proteins and ␣5 integrin could be due to the release of PDGF during the initial stages of wound healing to accelerate re-epithelization and scar tissue formation (Juhasz et al, 1993b) . Expression of ␣5 integrin after adenoviral injection with ␣5/Ad5 did not induce ␣2 integrin expression or vice versa, whereas PDGF-B induced both integrin subunits. Concomitant expression and, subsequently, changes in extracellular matrices may be the reason for the strong effects observed with PDGF-B. In a recent study, the induction of vascular endothelial growth factor (VEGF) in pericyte-like cells after PDGF-BB stimulation has been described (Reinmuth et al, 2001) . VEGF, in turn, is beneficial for the survival of endothelial cells. In this study, we found, by immunostaining for CD31 (PECAM-1), an increase in expression of chrondoitinsulfate proteoglycan, a marker for pericytes and vascular smooth muscle cells, as well as a dramatic increase in vessel formation, thus pinpointing the importance of PDGF-BB for modulating angiogenesis. Paracrine PDGF may also contribute to angiogenesis 
by increasing PDGFR-␤ mRNA in proliferating endothelial cells (Battegay et al, 1994) .
In a recent study, we used the adenoviral-mediated gene transfer of PDGF-B to investigate the potential usefulness of this approach in wounds of diabetic mice (Y Kitano, M Nesbit, M Herlyn, A Radu, KG Sylvester, NS Adzick, and TM Crombleholme, unpublished data). We found a significant enhancement in re-epithelialization, which was due to an induced accumulation of fibroblasts and endothelial cells. Extraction of PDGF from human skin after injection with PDGF-B/Ad5 in this study demonstrated that PDGF isoforms are indeed expressed at higher levels than in LacZ/Ad5-transduced samples. Further, we have shown that the adenoviral transfer of PDGF-B not only induced PDGF-A, but also PDGF-R␣ expression in fibroblasts, which is in accordance with a previous report about the induction of native PDGF-A by exogenous PDGF-B (Pierce et al, 1995) . Therefore, fibroblasts may amplify the effects of PDGF-B through PDGF receptors expressed on these cells. This process of receptor induction through continuous PDGF-B expression may also contribute to the in vivo changes observed in this study.
PDGF-B gene transfer in human skin led to a strong stimulatory effect of epidermal keratinocytes, which was already seen after 3 days. Keratinocytes do not express the receptor for PDGF-B and must be stimulated by other growth factors, possibly by the mitogen keratinocyte growth factor (Marchese et al, 1995) produced by PDGF-B-activated fibroblasts. In a preliminary study, where wounds of diabetic mice were treated with a PDGF-B adenoviral vector, we observed an increase in TGF-␣, which stimulates keratinocyte proliferation and migration. In this study, staining for undifferentiated keratinocytes with cytokeratins 5 and 8 at the Stratum basale revealed a dramatic increase in PDGF/Ad5-transduced human skin. PDGF-B transduction also leads to up-regulation of inflammatory factors. For example, monocyte chemoattractant protein-1 is up-regulated (Yoshimura and Leonard, 1990) , explaining the increased infiltration of mononuclear cells in grafts injected with PDGF-B/Ad5 when compared with grafts injected with the control vector. Also in this study, we found accumulation of murine macrophages in lesions of fibroblasts transduced with either PDGF-B or ␣5. However, in human skin grafts injected with the virus there were no changes regarding the infiltration of perilesional murine macrophages.
The paracrine stimulatory effects observed after PDGF-B transduction were not detected when ␣5 integrin/Ad5 was injected into the grafts, suggesting that the up-regulation of the adhesion receptor does not lead to increased production of growth factors. However, like PDGF-B, ␣5 injection led to an increase in fibronectin production, which was more clearly detectable in vivo in human skin than in cultured fibroblasts where serum-induced fibronectin production (not shown) obscured significant constructinduced increases. Likewise, ␣2 injection led to an increase in collagen synthesis. Up-regulation of collagen gene transcription by integrin ␣2␤1 has been shown recently (Ivaska et al, 1999) and involved the ␣2 cytoplasmic tail. The increased survival of fibroblasts after injection in vivo could be due to the expression of ␣5␤1 integrin in fibroblasts through PDGF-B or ␣5 transduction and the increased production of fibronectin. Thus, fibronectin may promote survival of fibroblasts in vivo and contribute to a lack of contact inhibition in vitro.
Long-term transforming effects of PDGF-B on human fibroblasts were not evident when the viral vector was directly injected into human skin, or when human fibroblasts were transduced in vivo followed by injection into SCID mice, suggesting that PDGF-B expression from an adenovirus does not lead to malignant transformation. The episomal nature of the adenovirus-mediated gene transfer does not allow for stable integration of the PDGF-B gene into the fibroblast genome (Kozarsky and Wilson, 1993) . This temporal expression of PDGF-B from an adenovirus and the effects elicited in vivo reflect the transient nature of the transformed phenotype observed in this study in vitro and in vivo.
Materials and Methods
Construction of Adenoviral Vectors for PDGF-B and ␣5
Integrin Subunit A 1.2 kbp PstI/EcoRI cDNA fragment, encoding the entire open reading frame of PDGF-B (Dr. B. Westermark, University Hospital, Uppsala, Sweden), was subcloned into the NotI-modified plasmid pSL301 (Vector Core, University of Pennsylvania, Philadelphia, Pennsylvania). The NotI fragments containing the PDGF-B open reading frame were cloned into the unique NotI site of the pAdCMV vector pSL301. A 3.7 kbp SalI-XbaI cDNA fragment of ␣5 integrin was cut from pECE (Dr. Erkki Ruoslahti, Burnham Institute, LaJolla, California) and ligated into XhoI-SpeI-cut pAdCMV-Link.1. Plasmids containing the PDGF-B or ␣5 integrin gene were cotransfected separately into human 293 cells (Rosenfeld et al, 1991) along with ClaI-digested dL7001 adenoviral genome (Ranheim et al, 1993) , in which both the E1 and E3 genes were deleted. Plaques were expanded in 293 cells and adenoviral DNA was isolated (Hirt, 1967) and digested with BamHI to determine the presence of the PDGF-B or ␣5 integrin gene by Southern blotting. Positive plaques were purified by two rounds of limited dilution cloning. Production of PDGF-B and ␣5 integrin proteins by fibroblasts transduced with PDGF-B/Ad5 and ␣5/Ad5, respectively, was confirmed by Western blotting. After bulk production in 293 cells, viral vectors were purified over cesium chloride step gradients by ultracentrifugation (Rosenfeld et al, 1991) , dialyzed against PBS, titrated for plaque-forming units (pfu), and stored in 10% glycerol at Ϫ80°C. 
Cell Lines and Growth Assays
Normal diploid human fibroblast cell lines were established from the dermis of human newborn foreskin (Cornil et al, 1991) and maintained in DMEM (Gibco/ BRL, St. Louis, Missouri) supplemented with 10% heat-inactivated FCS. NIH3T3 murine fibroblasts for growth stimulation assays and human 293 cells for adenovirus replication were also cultured in DMEM with 10% FCS. WM239A melanoma cells were maintained in MCDB 153 with 20% L-15 medium and supplemented with 2 mM Ca 2ϩ , 2% FCS, and 5 g/ml insulin.
[ 3 H]Thymidine incorporation into murine and human fibroblasts was measured by incubating cells in 96-well microtiter plates for 24 hours with 1 Ci/well. All data represent the mean of quadruplicate wells, and all assays were repeated twice. [
3 H]-Thymidine incorporation was performed the same way as mentioned above to demonstrate inhibition of PDGF-B-transduced fibroblast growth, except that 96-well microtiter plates were coated with fibronectin dissolved in PBS (pH 7.5) at 10 g/ml for 15 hours at 4°C. Fibroblasts were seeded and incubated with a human MAb against ␣5 (10 g/ml, PharMingen, San Diego, California) or unspecific human IgG MAb (100 g/ml) for 6 hours. To test for anchorage-independent growth in soft agar, 3 ϫ 10 4 cells were resuspended in 2 ml medium containing 0.3% Noble agar in 2% FCS and DMEM and seeded in 6-well plates coated with 0.5% agar in growth medium. Fresh overlay was added after 5 days, and the colony-forming efficiency was calculated based on the number of colonies of eight or more cells after 10 days. For in vivo growth studies, 1 ϫ 10 7 cells were injected subcutaneously into SCID mice per group. Mice were sacrificed 3, 10, 14, 21, or 60 days later to determine viability of the injected cells.
Immunoblotting and ELISA
Cell lysates (100 g) from transduced fibroblasts or WM239A cells were subjected to electrophoresis in 15% polyacrylamide gels, loading equal amounts of lysates onto gels (50 g per slot). Gels were electroblotted to polyvinylidene fluoride (PVDF) membranes, and PDGF-BB or ␣5 integrin subunit was detected using goat anti-PDGF-BB (R&D Systems, Minneapolis, Minnesota) or anti-␣5 integrin subunit MAbs (Transduction Labs., Lexington, Kentucky), respectively. Human skin, previously grafted onto SCID mice, was excised, placed on ice, and minced in ice-cold modified RIPA buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 5 mM EGTA; 0.1% SDS; 1% sodium deoxycholate; 1% NP-40; 0.5 mM sodium fluoride; and 100 M sodium orthovanadate). Equal amounts of lysates were loaded onto 15% polyacrylamide gels. After protein transfer to PVDF membranes, PDGF-AA or PDGF-AB/BB were detected using rabbit anti-human PDGF-AA (Santa Cruz, Biotechnology, Inc., Santa Cruz, California) or anti-human PDGF-AB/BB (PharMingen), respectively. Membranes were probed for ␤-actin expression with anti-␤-actin (SIGMA, St.
Louis, Missouri). Levels of PDGF-BB in human skin lysates were measured using an ELISA kit (Quantikine; R&D Systems).
Human Skin Grafting and Immunohistochemistry
Human neonatal foreskins were used for grafting within 48 hours after removal. At ages 8 to 12 weeks, recombination-activating gene 1 (RAG-1) (RAG-1/ RAG-1) or SCID mice, bred at the Wistar Institute Animal Facility (Philadelphia, Pennsylvania), were anesthetized and 1-to 3-cm 2 full-thickness cutaneous defects were created on the dorsal torso. Fullthickness human skin was sutured in place, and mice were used for experiments after 4 to 6 weeks when grafts were well healed. Xenografts were then injected intradermally with adenoviral vector at 5 ϫ 10 8 pfu in a total volume of 100 l PBS. Six mice were used for each group and killed at Days 3 and 7 for histological, histochemical, and immunohistochemical analyses of grafts.
Skin grafts were dissected free from surrounding murine tissue and bisected perpendicular to the long axis of the graft. Half of the graft was fixed overnight in 10% neutral buffered formalin at room temperature and paraffin-embedded. Serial sections were stained with H&E for pathohistological evaluation. Hoechst dye was used for nuclear staining to distinguish murine from human cells. The other half of each graft was embedded in OCT medium (Miles, Elkhart, Indiana), snap-frozen in liquid nitrogen, and cryosectioned at 5 m.
Immunohistochemistry was performed on serial cryosections using an avidin-biotin-peroxidase complex system (Vector Lab., Burlingame, California) and 3,3'-diaminobenzidine as chromagen. Tissue sections were fixed in acetone for 10 minutes at 4°C and incubated with primary antibodies in a humidified chamber overnight at 4°C. Antibodies used in the study include goat anti-human PDGF-BB (R&D Systems), anti-human ␣2 integrin subunit (PharMingen), anti-human CD31 (PECAM-1) (PharMingen), antihuman cytokeratins 5 and 8 (Zymed, San Francisco, California), anti-mouse CD11b (Mac-1 ␣ chain) (PharMingen), anti-human ␣5 integrin subunit (Transduction Labs), anti-human fibronectin (Novacastra, Newcastle, United Kingdom), and mouse antibodies IgG1, which recognize a chondroitin sulfate proteoglycan found on collagenous connective tissue, vascular smooth muscle cells, and pericytes (Ross et al, 1983) . After rinsing with PBS, sections were overlaid with biotinylated anti-mouse, -rabbit, or -goat IgG for 30 minutes at room temperature followed by staining.
